아밀로이드증 치료 시장 : 시장 예측(2026-2032년)

The Amyloidosis Treatment Market is projected to grow by USD 10.21 billion at a CAGR of 7.56% by 2032.

Amyloidosis Treatment Executive Summary

Amyloidosis treatment is entering a clinically dynamic phase as improved disease recognition, biomarker-led diagnosis, genetic testing, and organ-specific care pathways reshape how patients with systemic and localized amyloid disorders are managed. Amyloidosis refers to a group of rare, protein-misfolding diseases in which insoluble amyloid fibrils accumulate in organs such as the heart, kidneys, liver, gastrointestinal tract, and peripheral nerves. The treatment landscape is primarily influenced by amyloid type, including immunoglobulin light chain amyloidosis, transthyretin amyloidosis, amyloid A amyloidosis, dialysis-related amyloidosis, and hereditary variants. For light chain amyloidosis, therapy focuses on suppressing abnormal plasma cell activity and preventing irreversible organ damage. For transthyretin amyloidosis, approved approaches include transthyretin stabilizers, gene-silencing therapies, and supportive management for cardiomyopathy and polyneuropathy.

The clinical need remains substantial because delayed diagnosis is common, symptoms often overlap with heart failure, chronic kidney disease, neuropathy, and inflammatory disorders, and advanced organ involvement limits therapeutic reversibility. Evidence-based care increasingly depends on multidisciplinary coordination across hematology, cardiology, nephrology, neurology, pathology, nuclear medicine, and genetic counseling. In parallel, greater use of cardiac imaging, serum free light chain testing, immunofixation, cardiac biomarkers, mass spectrometry-based amyloid typing, and noninvasive bone scintigraphy for selected transthyretin cardiac cases is improving diagnostic accuracy. These shifts are expanding the role of precision medicine in amyloidosis treatment while emphasizing early intervention, longitudinal monitoring, and patient-centered management.

Transformative Shifts in the Amyloidosis Treatment Landscape

The amyloidosis treatment landscape is being transformed by earlier diagnosis, disease-modifying therapies, and a shift from symptom control toward targeted intervention. Historically, many patients were diagnosed only after advanced cardiac, renal, or neurologic impairment. Current clinical practice is moving toward structured screening in high-risk populations, including individuals with unexplained heart failure with preserved ejection fraction, increased ventricular wall thickness, bilateral carpal tunnel syndrome, spinal stenosis, biceps tendon rupture, autonomic neuropathy, proteinuria, monoclonal gammopathy, and family history of transthyretin variants. This earlier diagnostic orientation is particularly important because organ response and survival outcomes are strongly linked to treatment initiation before severe functional decline.

Therapeutic innovation is also changing care priorities. In light chain amyloidosis, plasma cell-directed regimens adapted from hematologic malignancy treatment are increasingly combined with rigorous organ response monitoring and supportive cardiac and renal care. In transthyretin amyloidosis, stabilizing and gene-silencing strategies are shifting treatment from palliation to disease modification, while emerging approaches targeting amyloid depletion, fibril clearance, and next-generation genetic medicines continue to attract clinical attention. At the same time, treatment delivery is being shaped by real-world challenges, including access to specialized diagnostic tools, reimbursement complexity, rare disease referral gaps, and the need for centers experienced in amyloid typing. The most important competitive differentiator for healthcare stakeholders is no longer a single therapeutic modality but the ability to integrate diagnosis, subtype confirmation, treatment selection, and long-term monitoring into a coordinated care model.

Cumulative Impact of Artificial Intelligence on Amyloidosis Care

Artificial intelligence is beginning to influence amyloidosis treatment by strengthening diagnostic suspicion, accelerating imaging interpretation, supporting risk stratification, and enabling more efficient clinical workflows. Because amyloidosis often presents with nonspecific symptoms, AI-enabled pattern recognition can assist clinicians in identifying red flags across electronic health records, laboratory trends, electrocardiograms, echocardiography reports, cardiac magnetic resonance imaging, claims data, and longitudinal medication histories. These tools are especially relevant for transthyretin cardiac amyloidosis, where delayed recognition among older adults with heart failure, conduction abnormalities, aortic stenosis, low-voltage electrocardiographic patterns, increased ventricular wall thickness, or carpal tunnel history remains a documented clinical concern.

AI also has cumulative impact across research and treatment development. Machine learning can improve patient identification for rare disease trials, refine phenotyping by integrating cardiac biomarkers, renal parameters, neuropathy measures, and imaging features, and support real-world evidence generation after therapy initiation. In pathology and proteomics, computational tools can assist amyloid detection and classification when used alongside validated laboratory methods, although expert confirmation remains essential. Importantly, AI adoption in amyloidosis care must be governed by data quality, algorithm transparency, clinical validation, privacy safeguards, and bias mitigation. Its greatest near-term value lies not in replacing specialist judgment but in reducing diagnostic delays, standardizing referral triggers, and helping multidisciplinary teams prioritize patients who require amyloid-specific evaluation.

Key Regional Insights Across Amyloidosis Treatment

In Asia-Pacific, amyloidosis treatment is shaped by expanding tertiary care capacity, growing access to advanced cardiac imaging, and increasing awareness of hereditary and age-related transthyretin amyloidosis in countries with rapidly aging populations. Japan has longstanding clinical experience in transthyretin disease, including neurologic and cardiac manifestations, while China, India, South Korea, and Australia are strengthening rare disease infrastructure, specialist referral networks, and access to genetic testing. However, availability of mass spectrometry-based amyloid typing, nuclear scintigraphy, and disease-modifying therapies remains uneven between major metropolitan centers and secondary-care settings.

North America demonstrates strong uptake of multidisciplinary amyloidosis programs, broad use of cardiac scintigraphy and biomarker monitoring, and high clinical trial activity across light chain and transthyretin amyloidosis. The United States and Canada benefit from established rare disease advocacy networks, advanced laboratory capabilities, genetic counseling services, and academic referral pathways, but diagnostic delay persists due to symptom overlap with more common cardiovascular, renal, and neurologic disorders.

Latin America is progressing through improved specialist awareness, expanding hematology and cardiology capabilities, and increasing recognition of amyloid cardiomyopathy in aging populations. Brazil and Mexico are central to regional development, with major urban hospitals supporting advanced diagnosis and specialist-led care. Access to amyloid typing, genetic testing, cardiac magnetic resonance imaging, scintigraphy, and disease-modifying therapies varies by public and private healthcare coverage, reinforcing the importance of practical referral protocols and clinician education.

Europe is characterized by structured referral systems, national rare disease strategies, and strong expertise in amyloid diagnostics, including mass spectrometry, nuclear imaging, cardiac magnetic resonance, and hereditary disease counseling. Countries within the region have advanced clinical networks for both light chain and transthyretin amyloidosis, supported by guideline-based care and specialist centers, though reimbursement timelines, health technology assessment outcomes, and access criteria differ across health systems.

The Middle East is seeing rising investment in specialty care, genetic medicine, and advanced cardiology services, particularly in high-income health systems. Consanguinity patterns in parts of the region increase the importance of genetic counseling and hereditary disease evaluation, while access to highly specialized amyloidosis centers remains concentrated in major urban hospitals. Standardized diagnostic algorithms can further support earlier recognition of cardiac, renal, and neurologic amyloidosis across the region.

Africa faces the greatest diagnostic and treatment access constraints, with limited availability of amyloid typing, advanced imaging, genetic testing, and rare disease-focused infrastructure in many settings. However, regional improvements in nephrology, cardiology, pathology, and genomic medicine are gradually creating opportunities for earlier recognition, particularly in urban referral centers, academic hospitals, and cross-border specialist collaborations.

Key Group Insights Across Amyloidosis Treatment

Across ASEAN, amyloidosis treatment development is influenced by increasing cardiovascular and renal disease screening, expanding private-sector specialty care, and the gradual integration of rare disease policies in selected member states. Access remains heterogeneous, with advanced diagnostics and disease-modifying therapies more concentrated in higher-income urban centers. As a result, physician education, laboratory capacity, and regional referral pathways are critical for improving diagnosis of light chain amyloidosis, transthyretin amyloidosis, and hereditary amyloid disorders.

The GCC is advancing amyloidosis care through investment in tertiary hospitals, genetic testing capacity, digital health infrastructure, and specialty cardiology and hematology services. The region's emphasis on precision medicine supports better hereditary amyloidosis recognition, while centralized health systems can facilitate earlier referral if standardized diagnostic algorithms are widely adopted. Greater integration of genetic counseling, family screening, and cardiac imaging protocols can strengthen care for patients with transthyretin variants and amyloid cardiomyopathy.

The European Union benefits from rare disease frameworks, cross-border reference networks, and regulatory pathways that support orphan medicines and clinical evidence generation. These structures strengthen amyloidosis diagnosis and treatment access by improving referral coordination, data sharing, and specialist collaboration. However, country-level reimbursement procedures, health technology assessments, and local implementation of clinical guidelines can affect the timing and consistency of patient access.

Within BRICS, amyloidosis treatment is shaped by large patient populations, uneven diagnostic access, and growing investment in advanced medical infrastructure. China, India, Brazil, Russia, and South Africa present diverse care environments, but all share the need for scalable screening strategies, local clinician training, and improved access to subtype-confirming diagnostics such as immunofixation, serum free light chain assays, tissue typing, nuclear imaging, and genetic testing.

G7 countries generally have stronger availability of specialist centers, clinical research participation, advanced imaging, molecular diagnostics, and evidence-based multidisciplinary care, enabling more comprehensive management of light chain and transthyretin amyloidosis. However, even in high-resource systems, delayed diagnosis remains a consistent challenge, reinforcing the need for primary care, cardiology, nephrology, hematology, and neurology awareness, especially for patients with unexplained heart failure, proteinuria, neuropathy, or monoclonal protein findings.

NATO member states include many health systems with mature rare disease capabilities and advanced cardiovascular care, but treatment access and diagnostic pathways vary widely across members. Harmonizing referral criteria, improving data sharing within ethical and regulatory limits, and strengthening military and veteran health system awareness may support earlier identification of amyloid cardiomyopathy and neuropathy in relevant populations, particularly where symptoms overlap with age-related cardiovascular or neurologic conditions.

Key Country Insights Across Amyloidosis Treatment

The United States leads in clinical adoption of multidisciplinary amyloidosis programs, broad specialist engagement, advanced imaging, and extensive use of biomarker-based monitoring, while Canada emphasizes coordinated care through academic centers, provincial health systems, and rare disease referral pathways. Mexico is improving recognition of amyloidosis through expanding cardiology and hematology expertise, although advanced diagnostic access remains concentrated in large cities. Brazil has growing expertise in amyloid cardiomyopathy and plasma cell disorders, supported by major urban specialty centers, while broader access depends on regional healthcare capacity, public coverage pathways, and availability of amyloid typing.

The United Kingdom has established specialist amyloidosis services and strong diagnostic expertise, particularly in amyloid typing, cardiac assessment, and organ response monitoring. Germany combines advanced cardiology, hematology, pathology, and nuclear medicine infrastructure with increasing recognition of transthyretin cardiomyopathy. France benefits from structured rare disease networks and specialist referral pathways, while Italy and Spain have active clinical expertise in cardiac and hereditary amyloidosis, supported by growing use of noninvasive diagnostic techniques. Russia has advanced specialty centers in major cities, though geographic scale can affect timely access to diagnosis, genetic counseling, and longitudinal management.

China is rapidly expanding rare disease policies, cardiovascular imaging capacity, and access to genetic testing, making it increasingly important in amyloidosis diagnosis and care model development. India faces a dual challenge of large unmet need and uneven access to advanced diagnostics, but major tertiary hospitals are improving recognition of light chain and transthyretin amyloidosis. Japan has deep experience with hereditary transthyretin amyloidosis and advanced management of cardiac and neurologic presentations, supported by specialist expertise and genetic evaluation. Australia benefits from specialized referral centers, genomic medicine capabilities, and rare disease coordination, while South Korea is strengthening precision diagnostics and specialist-led treatment pathways through advanced hospital networks.

Actionable Recommendations for Amyloidosis Treatment Leaders

Industry leaders should prioritize solutions that shorten the diagnostic journey, improve amyloid subtype confirmation, and connect patients with appropriate specialist care. The most actionable opportunity is to support evidence-based diagnostic algorithms for cardiology, nephrology, neurology, pathology, and hematology settings, especially where unexplained heart failure, increased ventricular wall thickness, proteinuria, nephrotic syndrome, neuropathy, monoclonal protein findings, bilateral carpal tunnel syndrome, or family history raise suspicion of amyloidosis. Education programs should focus on practical referral triggers, interpretation of serum free light chain testing and immunofixation, the role of cardiac scintigraphy in selected patients, genetic counseling requirements, and the importance of ruling out light chain amyloidosis before confirming transthyretin cardiac disease.

Stakeholders should invest in real-world evidence systems that capture diagnostic timelines, organ response, treatment persistence, safety outcomes, hospitalization patterns, functional status, and patient-reported quality of life. Partnerships with specialty centers can strengthen care pathway design, while digital decision support can improve early identification if clinically validated and embedded responsibly into workflows. Access strategies should be tailored to regional health system realities, including reimbursement requirements, diagnostic infrastructure, and availability of multidisciplinary expertise. For sustainable impact, industry leaders should align therapeutic innovation with patient navigation, laboratory capacity, clinician education, genetic counseling, and equitable access initiatives that address both high-resource and underserved settings.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in verified clinical, regulatory, epidemiological, and healthcare system evidence. The methodology emphasizes peer-reviewed medical literature, clinical practice guidelines, regulatory documentation, rare disease policy resources, health authority communications, and published data from recognized medical and scientific institutions. Sources are assessed for credibility, recency, methodological quality, and relevance to amyloidosis treatment, including light chain amyloidosis, transthyretin amyloidosis, hereditary forms, amyloid cardiomyopathy, renal amyloidosis, amyloid neuropathy, and systemic inflammatory amyloidosis.

The research process synthesizes information across disease biology, diagnostic pathways, therapeutic modalities, regional healthcare access, specialist infrastructure, and emerging technology adoption. Particular attention is given to evidence supporting early diagnosis, amyloid subtype confirmation, multidisciplinary management, biomarker monitoring, imaging use, genetic testing, organ response assessment, and patient outcomes. To maintain analytical integrity, this summary avoids unsupported claims, market sizing, market share analysis, and forecasts. The findings are presented as qualitative, data-backed insights intended to support strategic understanding of the amyloidosis treatment environment without implying quantitative market estimates.

Conclusion

Amyloidosis treatment is advancing from fragmented, late-stage management toward earlier, more precise, and multidisciplinary care. Progress is being driven by improved diagnostic tools, greater recognition of amyloid cardiomyopathy and neuropathy, increased use of genetic testing, biomarker-based monitoring, and disease-modifying therapies for key amyloid subtypes. Despite these advances, delayed diagnosis, unequal access to amyloid typing, limited specialist availability, and reimbursement variability continue to affect patient outcomes across regions.

The next phase of progress will depend on integrating clinical education, validated AI-supported screening, specialist referral networks, real-world evidence, and equitable access strategies. Healthcare stakeholders that align innovation with practical diagnostic pathways and patient-centered care coordination will be best positioned to improve outcomes in light chain amyloidosis, transthyretin amyloidosis, and related systemic amyloid disorders.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Amyloidosis Treatment Market, by Treatment Type

• 7.1. Introduction
• 7.2. Pharmacological Treatment
  • 7.2.1. Alkylating Agents
  • 7.2.2. Immunomodulators
  • 7.2.3. Monoclonal Antibodies
  • 7.2.4. Proteasome Inhibitors
    • 7.2.4.1. Bortezomib
    • 7.2.4.2. Carfilzomib
    • 7.2.4.3. Ixazomib
  • 7.2.5. TTR Silencers
    • 7.2.5.1. Inotersen
    • 7.2.5.2. Patisiran
  • 7.2.6. TTR Stabilizers
    • 7.2.6.1. Acoramidis
    • 7.2.6.2. Tafamidis
• 7.3. Stem Cell Transplantation
• 7.4. Supportive Therapy

8. Amyloidosis Treatment Market, by Route Of Administration

• 8.1. Introduction
• 8.2. Intravenous
• 8.3. Oral
• 8.4. Subcutaneous

9. Amyloidosis Treatment Market, by Amyloidosis Type

• 9.1. Introduction
• 9.2. Hereditary ATTR
• 9.3. Wild-Type ATTR

10. Amyloidosis Treatment Market, by End User

• 10.1. Introduction
• 10.2. Home Care
• 10.3. Hospital
• 10.4. Specialty Clinic

11. Amyloidosis Treatment Market, by Therapy Modality

• 11.1. Introduction
• 11.2. Disease Modifying Therapy
• 11.3. Symptom Management Therapy
• 11.4. Amyloid Reduction Therapy

12. Amyloidosis Treatment Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Amyloidosis Treatment Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Amyloidosis Treatment Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AbbVie Inc.
• 16.2. Alnylam Pharmaceuticals Inc.
• 16.3. Amgen Inc.
• 16.4. Arcturus Therapeutics Holdings Inc.
• 16.5. AstraZeneca PLC
• 16.6. Attralus Inc.
• 16.7. BridgeBio Pharma Inc.
• 16.8. Bristol-Myers Squibb Company
• 16.9. Corino Therapeutics Inc.
• 16.10. CRISPR Therapeutics AG
• 16.11. CSL Vifor
• 16.12. F. Hoffmann-La Roche Ltd
• 16.13. Genmab A/S
• 16.14. GlaxoSmithKline plc
• 16.15. Intellia Therapeutics Inc.
• 16.16. Ionis Pharmaceuticals Inc.
• 16.17. Johnson & Johnson Services Inc.
• 16.18. Merck KGaA
• 16.19. Neurimmune AG
• 16.20. Novartis AG
• 16.21. Pfizer Inc.
• 16.22. Proclara Biosciences Inc.
• 16.23. Prothena Corporation plc
• 16.24. Regeneron Pharmaceuticals Inc.
• 16.25. Sanofi SA
• 16.26. Silence Therapeutics plc
• 16.27. Som Biotech SL
• 16.28. Takeda Pharmaceutical Company Limited
• 16.29. Vertex Pharmaceuticals Inc.